IndieBio – now operating out of both San Francisco and New York – is proud to announce our new batches of startups. This is New York’s first batch, and San Francisco’s tenth. Though we are [...]
The large, systemic problems facing humanity have never been clearer, nor has the need for innovative biotech solutions for these problems. The new IndieBio New York program, launching May 2020, [...]
Announcement We are seeking up to 8 startups to receive a minimum of $250,000 each to pursue the development of diagnostics, therapeutics, vaccines, disinfection, and other solutions addressing [...]
IndieBio helps entrepreneurs build ground-breaking biotech companies. We’re excited to share our ninth class of 11 new startups. They have been here for thirty days, working tirelessly to derisk [...]
Beeline takes engineered immune cell therapy in a new direction. They are unique in how they have engineered regulatory T cells (Tregs), which play a natural role in ramping down the immune [...]
Gavilán Biodesign emerged out of the Donald Lab at Duke University, one of the world leaders in computational drug design. During their time at Duke, they redesigned many compounds, including a [...]
The CRISPR Cas complex has been a game-changing technology for gene editing. CASPR Biotech is using the incredible accuracy of CRISPR for something different — to revolutionize medical [...]
At IndieBio, our perspective on gut bacteria is informed not just by the companies we’ve invested in that do human microbiome science, but by all the companies in our portfolio who work with [...]
We’re excited to announce our eighth class at IndieBio. IndieBio invests in revolutionary technologies for human and planetary health, and each of these companies, though small today, has [...]
